Skip to main content

Infectious Disease Dynamics

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
Search

Search form

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
  • Home
  • Projects
  • Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

The capacity to accurately estimate incidence of HIV and HCV from cross sectional surveys is critical to the determining the current state of the epidemic and assessing the impact of population level interventions. These methodologies are used for country level incidence estimates, such as the Population-based HIV Impact Assessment (currently being performed in 15 countries receiving PEPFAR funding), large intervention trials, and at an individual level (for all newly diagnosed persons in the UK).

Using biomarkers associated with recent infection, we have developed and validated testing algorithms to generate point estimates of incidence and incidence differences between paired surveys.  Both serologic (properties of the antibody response) and nucleic acid (viral diversity) have been exploited for this purpose.

Publications

High HIV burden among people who inject drugs in 15 Indian cities.
Lucas GM, Solomon SS, Srikrishnan AK, Agrawal A, Iqbal S, Laeyendecker O, McFall AM, Kumar MS, Ogburn EL, Celentano DD, Solomon S, Mehta SH.
AIDS, 2015: 29(5): 619-628, 10.1097/QAD.0000000000000592
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.
Laeyendecker O, Redd AD, Nason M, Longosz AF, Karim QA, Naranbhai V, Garrett N, Eshleman SH, Abdool Karim SS, Quinn TC.
J Infect Dis, 2015: 212(5): 754-759, 10.1093/infdis/jiv110
Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D.
Longosz AF, Morrison CS, Chen PL, Brand HH, Arts E, Nankya I, Salata RA, Quinn TC, Eshleman SH, Laeyendecker O.
AIDS Res Hum Retroviruses, 2015: 31(4): 421-427, 10.1089/AID.2014.0081
HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithm.
Cousins MM, Konikoff J, Laeyendecker O, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Koblin BA, Wheeler D, Justman JE, Hodder SL, Quinn TC, Brookmeyer R, Eshleman SH.
J Clin Microbiol, 2014: 52(1): 115-21, 10.1128/JCM.02040-13
Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda.
Longosz AF, Serwadda D, Nalugoda F, Kigozi G, Franco V, Gray RH, Quinn TC, Eshleman SH, Laeyendecker O.
AIDS Res Hum Retroviruses, 2014: 30(4): 339-44, 10.1089/AID.2013.0169
Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users.
Etemad B, Gonzalez OA, White L, Laeyendecker O, Kirk GD, Mehta S, Sagar M.
Retrovirology, 2014: 11: 106, 10.1186/s12977-014-0106-8
Response to using incidence assays within the context of the recent infections testing algorithm.
Laeyendecker O, Brookmeyer R.
AIDS, 2014: 28(14): 2168, 10.1097/QAD.0000000000000368
A serial risk score approach to disease classification that accounts for accuracy and cost.
Huynh D, Laeyendecker O, Brookmeyer R.
Biometrics, 2014: 70(4): 1042-1051, 10.1111/biom.12217

Pages

  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • next ›

Contact

Tel: xxx-xxx-xxxx

Email: iddynam [at] jhu.edu

Infectious Disease Dynamics Group
c/o Amy Wesolowski
Johns Hopkins Bloomberg School of Public Health
615 North Wolfe Street, E6516
Baltimore MD 21205

Social

Twitter
 
  • Disclaimer & Privacy
  • Sitemap
© 2022 Infectious Disease Dynamics
Website by Manta Ray Media